IDEXX Laboratories Inc
IDXX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000874716
In the last 90 days, IDEXX Laboratories Inc insiders filed 0 open-market purchases and 5 sales; 1,312 institutions reported holding it in 13F filings for Q2 2026, worth $39.1B in total; 3 superinvestors hold it, including Fundsmith and Weitz Investment Management.
Key figures
- Market capClose on Nov 11, 2026
- $55.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $28.6M in total
- 5
- 13F holdersQ2 2026, +8 vs. previous quarter
- 1,312
- 13F valueReported value at the end of Q2 2026
- $39.1B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $4.30B
- +10.4% year over year
- Net income, FY2025
- $1.06B
- +19.3% year over year
- Free cash flow, FY2025
- $1.06B
- +30.8% year over year
- Revenue, Q3 FY2026
- $1.21B
- +9.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.35M
- Shares sold short
- Change
- +424.8K
- +22.0% vs. previous
- Days to cover
- 4.45
- At average daily volume
Superinvestors holding IDXX, Q2 2026
Go to the superinvestors tab3 superinvestors report holding IDEXX Laboratories Inc on Form 13F. Percentages are the stock's share of each portfolio.
Weitz Investment Management
Wally Weitz
1.3%
IDEXX Laboratories Inc's share of the portfolio
- Shares
- 35,300
- Value
- $18.6M
| Superinvestor | Weight | Value |
|---|---|---|
| Harris Associates (Oakmark) | <0.1% | $239.5K |
Latest insider trades
See all insider tradesOpen-market purchases and sales by IDEXX Laboratories Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)5:02 PM ET | Nov 4 | 1 day | Underberg Sharon E.EVP, GC & Corporate Secretary | SSale | −8.91K | $688.59 | −$6.13M | −55.4%7.17K after | 3 lots |
| Nov 5, 2026 (view filing)5:01 PM ET | Nov 4 | 1 day | Mazelsky Jonathan JayExecutive Chair of the Board | SSale | −25.1K | $703.19 | −$17.7M | −23.1%83.8K after | 13 lots |
| Nov 5, 2026 (view filing)5:01 PM ET | Nov 4 | 1 day | Lane MichaelExecutive Vice President | SSale | −3.98K | $688.64 | −$2.74M | −49.4%4.08K after | 3 lots |
| Nov 5, 2026 (view filing)5:01 PM ET | Nov 4 | 1 day | Junius Daniel MDirector | SSale | −1.20K | $704.07 | −$844.9K | −33.7%2.36K after | 2 lots |
| Sep 9, 2026 (view filing)5:00 PM ET | Sep 4 | 5 days | Kingsley Lawrence DDirector | SSale | −2.20K | $532.08 | −$1.17M | −18.7%9.57K after | |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Hunt NimrataExecutive Vice President | SSale | −1.76K | $634.57 | −$1.12M | −8.8%18.1K after | |
| Mar 2, 2026 (view filing) | Feb 26 | 4 days | Mazelsky Jonathan JayPresident and CEO | SSale | −23.3K | $657.55 | −$15.3M | −21.8%83.6K after | 13 lots |
| Feb 27, 2026 (view filing) | Feb 26 | 1 day | Hunt NimrataExecutive Vice President | SSale | −2.69K | $661.54 | −$1.78M | −11.9%19.9K after | |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Erickson Michael GExecutive Vice President | SSale | −5.37K | $627.38 | −$3.37M | −29.7%12.7K after | 6 lots |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Vandebroek Sophie V.Director | SSale | −1.46K | $628.62 | −$920.3K | −69.3%648 after | 2 lots |
Top 10 13F holders, Q2 2026
See all 1,312 holdersThe largest institutional positions in IDEXX Laboratories Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,170,178 | $4.30B | 0.06% | −195,375−2.3% | Reduced |
| Vanguard Capital Management LLC | 5,152,213 | $2.71B | 0.06% | −30,294−0.6% | Reduced |
| Vanguard Portfolio Management LLC | 3,896,521 | $2.05B | 0.09% | −14,342−0.4% | Reduced |
| State Street Corp | 3,748,660 | $1.97B | 0.06% | +74,475+2.0% | Added |
| Invesco Ltd. | 3,611,416 | $1.90B | 0.15% | +261,739+7.8% | Added |
| Geode Capital Management, LLC | 2,562,886 | $1.35B | 0.07% | −98,113−3.7% | Reduced |
| Bamco Inc | 1,976,778 | $1.04B | 1.56% | +343,411+21.0% | Added |
| Morgan Stanley | 1,356,103 | $713.9M | 0.04% | +40,149+3.1% | Added |
| Bank of New York Mellon Corp | 1,193,343 | $628.2M | 0.10% | −311,189−20.7% | Reduced |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | $561.8M | 0.25% | +228,239+27.2% | Added |
Holders of 5% or more of IDXX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of IDEXX Laboratories Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 9.40%7.60M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Vanguard Capital Management LLC | 13G | 7.51%5.98M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
| Vanguard Portfolio Management LLC | 13G | 5.04%3.97M shares | New | Oct 30, 20261 filing | Oct 30, 2026 | SEC |
Politician trades
All politician trades in IDXX7 members of Congress reported 29 trades in IDEXX Laboratories Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Feb 2, 2026 |  April McClain Delaney House · MD | Sell | $1K-$15K |
| Jan 5, 2026 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Nov 4, 2025 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Nov 4, 2025 | April McClain Delaney House · MD | Sell (partial) | $1K-$15K |
| Oct 7, 2025 |  Byron Donalds House · FL | Buy | $1K-$15K |
House · MD · Feb 2, 2026
Sell$1K-$15K
House · MD · Jan 5, 2026
Sell (partial)$1K-$15K
House · MD · Nov 4, 2025
Sell (partial)$1K-$15K
House · MD · Nov 4, 2025
Sell (partial)$1K-$15K
House · FL · Oct 7, 2025
Buy$1K-$15K